Search results for " Mucosal"

showing 10 items of 72 documents

Prevalence of oral lichen planus among a sample of the Egyptian population

2015

Objectives: To report on the prevalence of oral lichen planus among a sample of the Egyptian population. Study Design: 4470 Egyptian patients, aged 15-75 years, were seen at the outpatient clinic at the Faculty of Oral and Dental Medicine, Cairo University, Egypt. 31.25 % of these patients were males and 68.75% were females. Oral mucosal lesions consistent with oral lichen planus (OLP) were identified both clinically and confirmed histo - logically (in atypical cases) so that the prevalence of oral lichen planus in this study is 1.43%. Results: 64 patients were diagnosed with OLP (20 males and 44 females). The average age of the affected group was 48.07 years. Associated skin lesions were d…

Pathologymedicine.medical_specialtyPopulationOdontologíaLesionstomatognathic systemDiabetes mellitusmedicineOutpatient clinicBasal celleducationGeneral Dentistryeducation.field_of_studyOral Medicine and Pathologyintegumentary systembusiness.industryResearchCirculating antibodiesOral mucosal lesionsmedicine.disease:CIENCIAS MÉDICAS [UNESCO]DermatologyCiencias de la saludstomatognathic diseasesUNESCO::CIENCIAS MÉDICASOral lichen planusmedicine.symptombusiness
researchProduct

Mucoadhesive polymers for oral transmucosal drug delivery: a review.

2012

The oral mucosa offers an interesting site for the application of dosage forms that release drugs within/throughout the oral mucosa, by assuring a high drug bioavailability for topic and systemic effects. However, the relative permeability of the oral mucosa and the washing effect related to the oral fluids and mechanical stresses must be considered in the formulation of oral dosage forms. Since a sustained drug release can be guaranteed only if dosage forms remain in contact with the oral site of absorption/application for a prolonged time, the development of mucoadhesive dosage forms is mandatory. The mucoadhesion is a complex phenomenon and the mucoadhesive bond consists of two different…

PolymersBiological AvailabilityPharmacologyDosage formDelayed-Action PreparationsMucoadhesive polymersDrug Delivery SystemsSettore MED/28 - Malattie OdontostomatologicheDrug DiscoverymedicineMucoadhesionAnimalsHumansOral mucosaPharmacologyChemistryMouth MucosaAdhesivenessBioavailabilitymedicine.anatomical_structurePharmaceutical PreparationsMucoadhesion oral transmucosal drug delivery dosage form drug controlled-release mucoadhesive polymers oral mucosa mucosal permeabilitySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDelayed-Action PreparationsDrug deliveryDrug releaseCurrent pharmaceutical design
researchProduct

Polypoid anal melanoma. A case report and review of the literature

2016

Ano-rectal melanoma is an uncommon finding in patients complaining of rectal bleeding and/or anal mass often misinterpreted as a haemorroidal pile.A 55-years-old woman, complaining of rectal bleeding, frequent anal pain and anal mass suspected for haemorroidal thrombosis was referred for evaluation and possible treatment. A brown polypoid mass arising from the anal canal/lower rectum with a maximum diameter of 6 cm was diagnosed. The hystological examination of the neoplasm, transanally removed, revealed the presence of a polypoid melanoma partially involving the resection margin. Nor metastases nor limph-node involvement were found at the total-body CT scan and at a CT-PET. C-KIT examinati…

PrognosiHemorrhoidsDiagnosis DifferentialTreatment RefusalAnus NeoplasmAntineoplastic Combined Chemotherapy ProtocolsHumansmucosal melanomaNeoplasm Invasivenessrectal bleedingMelanomaDigestive System Surgical ProceduresNeoplasm InvasiveneAntineoplastic Combined Chemotherapy Protocolano-rectal melanoma; mucosal melanoma; rectal bleedingRectal DiseaseDigestive System Surgical ProcedureMiddle AgedAnus NeoplasmsPrognosisRectal DiseasesChemotherapy Adjuvantano-rectal melanomaFemaleHemorrhoidGastrointestinal HemorrhageHuman
researchProduct

Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications.

2007

Inflammatory bowel diseases (IBDs) such as Crohn’s disease and ulcerative colitis are the result of an imbalanced mucosal T cell response. Despite the identification of a genetic susceptibility region in the NOD2/CARD15 (nucleotide-binding oligomerisation domain 2/caspase recruitment domain 15) gene, the aetiology is still unclear. Thus, the hunt for disease-initiating factors such as defects in the mucosal barrier or pathogenic microorganisms is ongoing. By contrast, the immunopathogenesis in IBDs is better understood. The identification of cytokines that are involved in T cell and monocyte signalling led to specific therapeutic concepts. Recent data have clearly shown that the most powerf…

Programmed cell deathNecrosisCell Survivalmedicine.medical_treatmentT cellT-LymphocytesApoptosisImmune systemCrohn DiseaseNOD2AzathioprinemedicineHumansIntestinal MucosaMesalamineImmunity Mucosalbusiness.industryInterleukin-6Tumor Necrosis Factor-alphaAnti-Inflammatory Agents Non-SteroidalGastroenterologyRecent Advances in Basic ScienceInflammatory Bowel DiseasesInterleukin-12Immunosuppressive drugmedicine.anatomical_structureApoptosisImmunologyTumor necrosis factor alphamedicine.symptombusinessImmunosuppressive AgentsSignal TransductionGut
researchProduct

Expression of B-Cell Activating Factor Enhances Protective Immunity of a Vaccine against Pseudomonas aeruginosa

2009

ABSTRACT B-cell activating factor (BAFF), a member of the TNF family, is a potent cytokine with stimulatory effects on B and T cells. To evaluate the potential of transient overexpression of BAFF to enhance vaccine immunogenicity, a replication-deficient adenovirus expressing full-length murine BAFF (AdBAFF) was tested in a mouse vaccine model against Pseudomonas aeruginosa . When coadministered with heat-killed P. aeruginosa , AdBAFF mediated a significant increase in anti- P. aeruginosa- specific serum and lung mucosal antibodies and resulted in improved protection against a lethal respiratory challenge with P. aeruginosa . This effect was independent of the site of administration of AdBA…

Pseudomonas Vaccinesmedicine.medical_treatmentGenetic VectorsImmunologyBiologymedicine.disease_causeMicrobiologyAdenoviridaeMicrobiologyMiceImmune systemAdjuvants ImmunologicImmunityB-Cell Activating FactorPneumonia BacterialmedicineAnimalsB-cell activating factorImmunity MucosalPseudomonas aeruginosaAntibodies BacterialSurvival AnalysisMice Inbred C57BLInfectious DiseasesCytokineVaccines InactivatedImmunizationMicrobial Immunity and VaccinesPseudomonas aeruginosaImmunologybiology.proteinFemaleParasitologyAntibodyAdjuvantInfection and Immunity
researchProduct

Distribution and phenotype of rotavirus-specific B cells induced during the antigen-driven primary response to 2/6 virus-like particles administered …

2007

AbstractSelection of mucosal sites is an important step in mucosal vaccine development. The intrarectal (IR) route represents an alternative to the oral route of immunization; nevertheless, immune responses induced by this route are not well defined. Here, we studied the early primary B cell response (induction, homing, and phenotype) induced by IR immunization with rotavirus (RV)-2/6 virus-like particles (VLP). Using flow cytometry, we traced RV-specific B cells in different lymphoid tissues and analyzed the expression of α4β7 and CCR9, which are important receptors for homing to the gut, as well as CD5, a marker expressed by B1-a cells, which are a major source of natural antibodies. We o…

RotavirusAntibodies ViralMicePeyer's Patches0302 clinical medicineCell MovementImmunology and AllergyMesenteric lymph nodes[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyMesenteryAntigens ViralmucosaB-LymphocytesMice Inbred BALB C0303 health sciencesmedicine.diagnostic_testrodent3. Good healthIntestinesPhenotypemedicine.anatomical_structure[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleAntibodyImmunologyReceptors Lymphocyte HomingBiologyCD5 AntigensFlow cytometryReceptors CCR03 medical and health sciencesImmune systemAntigenmedicineAnimalsImmunity MucosalAdministration IntranasalB cell030304 developmental biologyLumbosacral RegionRotavirus VaccinesCell BiologyvaccinationB-1 cellB-1a cellsImmunologybiology.proteinImmunizationLymph Nodescell traffickingCD5030215 immunology
researchProduct

Different profile and distribution of antigen specific T cells induced by intranasal and intrarectal immunization with rotavirus 2/6-VLP with and wit…

2013

International audience; In this study, we compared both the profile and distribution of antigen specific primed T cells after intrarectal (IR) and intranasal (IN) immunization with rotavirus (RV) 2/6-VLP, alone or in the presence of LT-R192G, in order to highlight the differences between the two routes and the impact of the adjuvant. Adult BALB/c mice were immunized once with 2/6-VLP with or without adjuvant and the T cell response was analyzed in lymphoid tissues after in vitro restimulation with the antigen. IN, but not IR, immunization of mice with 2/6-VLP alone induced antigen-specific IL-10 and IL-17 secreting T cells. IL-10-, in contrast to IL-17-, secreting T cells did not migrate to…

Rotavirusmedicine.medical_treatmentT-Lymphocytes[SDV]Life Sciences [q-bio]Priming (immunology)DistributionPHENOTYPEPROTECTSEnterotoxins0302 clinical medicineCell MovementINFECTIONMesenteric lymph nodesHEAT-LABILE TOXINIMMUNE-RESPONSEIL-2 receptorAntigens Viral0303 health sciencesB-LymphocytesMice Inbred BALB CIntrarectalEscherichia coli ProteinsVaccinationFOXP3CHOLERA-TOXINLT-R192G3. Good healthInfectious Diseasesmedicine.anatomical_structureIntranasal030220 oncology & carcinogenesisMolecular MedicineFemaleAdjuvantLymphoid TissueT cellBacterial ToxinsSpleenBiologyMUCOSAL VACCINESRotavirus Infections03 medical and health sciencesCross-PrimingAntigenAdjuvants ImmunologicAdministration RectalVIRUS-LIKE PARTICLESmedicineAnimalsVaccines Virus-Like ParticleImmunity MucosalAdministration Intranasal030304 developmental biologyGeneral VeterinaryGeneral Immunology and MicrobiologyInterleukinsPublic Health Environmental and Occupational HealthRotavirus VaccinesT cellMICEImmunologyCHALLENGE
researchProduct

Patients' Acceptability of Different Fentanyl Products for Breakthrough Cancer Pain

2014

OTFC (6) 1.7 (0.5) 1.5 (0.5) 2.0 (0.6) 1.5 (0.8) 1.5 (0.5) 33.1 (43.5) FBT (19) 2.0 (0.6) 2.0 (0.7) 1.8 (0.7) 1.8 (0.8) 1.9 (0.7) 15.9 (7.3) SLF (37) 2.1 (0.5) 2.2 (0.4) 1.8 (0.4) 2.0 (0.6) 2.1 (0.5) 16.7 (12.5) INFS (7) 2.1 (0.4) 2.1 (0.4) 2.0 (0.6) 2.0 (0.8) 2.0 (0.8) 15.7 (13.7) PFEN (11) 2.4 (0.5) 2.2 (0.4) 1.8 (0.4) 1.9 (0.7) 2.1 (0.5) 15.0 (13.7) P 0.120 0.043* 0.870 0.595 0.178 0.015x *,x Oral transmucosal fentanyl was significantly considered to be more problematic.

Settore MED/06 - Oncologia Medicabusiness.industryBreakthrough PainBreakthrough PainPatient Acceptance of Health CareSettore MED/42 - Igiene Generale E ApplicatafentanylFentanylbreakthrough cancer painBTPOncologyNeoplasmsAnesthesiaAdministration MucosalHumansMedicineRadiology Nuclear Medicine and imagingpatient's preferencefentanyl; breakthrough cancer pain; BTP; patient's preferencebusinessCancer painmedicine.drugClinical Oncology
researchProduct

Physical Methods for Enhancing Oral Mucosal Delivery: Sonophoresis, Iontophoresis and Electroporation

2015

The need for more rapid onset of action and improved absorption of medications has resulted in great development of drug delivery technologies. Transmucosal drug delivery offers a convenient route of administration for a variety of clinical indications. Unfortunately, the wide variability in structure of the oral mucosal tissues could constitute a key factor in drug penetration and absorption. To circumvent this obstacle and to increase the drug flux through the mucosal membranes, different approaches to permeation enhancement are used. This chapter describes the most significant aspects of the physical techniques widely used such as sonophoresis, iontophoresis, and electroporation. These p…

Sonophoresis iontophoresis electromigration electroosmosis electroporation physical permeation enhancement oral mucosal deliveryIontophoresisSettore CHIM/09 - Farmaceutico Tecnologico Applicativobusiness.industryElectroporationRapid onsetDrug deliveryMedicineAbsorption (skin)PharmacologybusinessSonophoresis
researchProduct

Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question.

2001

T-cell resistance against apoptosis contributes to inappropriate T-cell accumulation and the perpetuation of chronic mucosal inflammation in inflammatory bowel diseases (IBDs). Anti-interleukin-12 (IL-12) and anti-IL-6 receptor antibodies suppress colitis activity by the induction of T-cell apoptosis. These findings have important implications for the design of effective treatment regimens in IBD.

T-LymphocytesImmunologyApoptosisInflammatory bowel diseaseImmunology and AllergyMedicineEffective treatmentAnimalsHumansColitisIntestinal MucosaReceptorImmunity MucosalT-cell apoptosisbiologyCell Deathbusiness.industryInflammatory Bowel Diseasesmedicine.diseaseInflammatory Bowel Diseasesdigestive system diseasesApoptosisImmunologybiology.proteinAntibodybusinessTrends in immunology
researchProduct